<DOC>
	<DOCNO>NCT01142219</DOCNO>
	<brief_summary>One main problem sickle cell disease decrease bioavailability nitric oxide arginine . This study design assess treat sickle cell disease patient L-arginine would improve pulmonary arterial pressure aspect .</brief_summary>
	<brief_title>L-Arginine Sickle Cell Disease</brief_title>
	<detailed_description>This phase III , randomize , double-blind , placebo-controlled clinical trial sickle cell disease patient older 1 year age . The patient randomly assign take 0.1 g/kg/day either L-arginine placebo orally . Adverse event monitor safety committee . The variable assess patient remission , part routine care : weight , blood pressure , full blood cell count , creatinine dosage methemoglobin baseline follow-up visit . Peripheral oxygen saturation ( SpO2 ) , fetal hemoglobin , lactate dehydrogenase tricuspid regurgitant jet velocity measure transthoracic Doppler echocardiogram treatment .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Diagnosis sickle cell disease confirm hemoglobin electrophoresis Genotypes SS , SC SÎ² thalassemia Age &gt; 1 year Liver dysfunction ( alanine aminotransferase ALT &gt; 3 time normal level Renal dysfunction ( creatinine &gt; twice normal level ) Increase methemoglobin level ( &gt; 5 time normal level ) History recent stroke ( &lt; 1 month ) priapism Pregnancy Allergy Larginine Use sildenafil , calcium channel blocker , nitroglycerin nitrate</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>L-arginine</keyword>
	<keyword>hemolysis</keyword>
	<keyword>nitric oxide</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
</DOC>